Advertisement

Islet Cell or Pancreas Transplantation

  • Lorenzo Piemonti
  • Carlo Socci
  • Rita Nano
  • Paola Maffi
  • Antonio Secchi
Reference work entry
Part of the Endocrinology book series (ENDOCR)

Abstract

Islet cell or pancreas transplantation is the only long-term diabetes treatment that consistently results in normal hemoglobin A1c levels without the risk of severe hypoglycemia. Additionally, islet cell or pancreas transplantation may prevent, halt, or even reverse the complications of diabetes. Consequently, it is an important part of the management of a subset of patients with diabetes, namely, those in renal failure and those with life-threatening complications of their diabetes such as hypoglycemic unawareness. Here, we explore the indications, options, and outcomes of islet cell or pancreas transplantation as a treatment for diabetes mellitus. The morbidity of solid-organ pancreas transplantation restricts pancreas transplantation to relatively younger and fitter patients. Islet cell transplantation is less invasive and, therefore, more appealing to patients, endocrinologists, and diabetologists. Pancreas transplants and islet transplants should be considered complementary, not mutually exclusive, procedures that are chosen on the basis of the individual patient’s surgical risk. As the mortality and morbidity of solid pancreas transplantation diminish and the longer-term outcomes of both solid-organ and islet transplantation improve, the appropriate indications for both procedures will expand, particularly with the increasing incidence of diabetes as well as evidence that transplantation is suitable not only for type 1 diabetics but also for selected insulin-dependent patients with type 2 diabetes.

Keywords

Pancreas transplantation Islet transplantation 

References

  1. Alejandro R, Barton FB, et al. 2008 Update from the collaborative islet transplant registry. Transplantation. 2008;86(12):1783–8.PubMedCrossRefGoogle Scholar
  2. Andres A, Toso C, et al. Impairment of renal function after islet transplant alone or islet-after-kidney transplantation using a sirolimus/tacrolimus-based immunosuppressive regimen. Transpl Int. 2005;18(11):1226–30.PubMedCrossRefGoogle Scholar
  3. Badell IR, Russell MC, et al. LFA-1-specific therapy prolongs allograft survival in rhesus macaques. J Clin Invest. 2010;120(12):4520–31.PubMedPubMedCentralCrossRefGoogle Scholar
  4. Baghurst PA. Calculating the mean amplitude of glycemic excursion from continuous glucose monitoring data: an automated algorithm. Diabetes Technol Ther. 2011;13(3):296–302.PubMedCrossRefGoogle Scholar
  5. Balamurugan AN, Naziruddin B, et al. Islet product characteristics and factors related to successful human islet transplantation from the collaborative islet transplant registry (CITR) 1999–2010. Am J Transplant. 2014;14(11):2595–606.PubMedPubMedCentralCrossRefGoogle Scholar
  6. Ballinger WF, Lacy PE. Transplantation of intact pancreatic islets in rats. Surgery. 1972;72(2):175–86.PubMedGoogle Scholar
  7. Barkai U, Weir GC, et al. Enhanced oxygen supply improves islet viability in a new bioartificial pancreas. Cell Transplant. 2013;22(8):1463–76.PubMedCrossRefGoogle Scholar
  8. Barshes NR, Lee TC, et al. Transaminitis after pancreatic islet transplantation. J Am Coll Surg. 2005a;200(3):353–61.PubMedCrossRefGoogle Scholar
  9. Barshes NR, Vanatta JM, et al. Health-related quality of life after pancreatic islet transplantation: a longitudinal study. Transplantation. 2005b;79(12):1727–30.PubMedCrossRefGoogle Scholar
  10. Barton FB, Rickels MR, et al. Improvement in outcomes of clinical islet transplantation: 1999–2010. Diabetes Care. 2012;35(7):1436–45.PubMedPubMedCentralCrossRefGoogle Scholar
  11. Bassi R, Fiorina P. Impact of islet transplantation on diabetes complications and quality of life. Curr Diab Rep. 2011;11(5):355–63.PubMedCrossRefGoogle Scholar
  12. Bazerbachi F, Selzner M, et al. Portal venous versus systemic venous drainage of pancreas grafts: impact on long-term results. Am J Transplant. 2012;12(1):226–32.PubMedCrossRefGoogle Scholar
  13. Becker BN, Brazy PC, et al. Simultaneous pancreas-kidney transplantation reduces excess mortality in type 1 diabetic patients with end-stage renal disease. Kidney Int. 2000;57(5):2129–35.PubMedCrossRefGoogle Scholar
  14. Bellin MD, Kandaswamy R, et al. Prolonged insulin independence after islet allotransplants in recipients with type 1 diabetes. Am J Transplant. 2008;8(11):2463–70.PubMedPubMedCentralCrossRefGoogle Scholar
  15. Bellin MD, Barton FB, et al. Potent induction immunotherapy promotes long-term insulin independence after islet transplantation in type 1 diabetes. Am J Transplant. 2012;12(6):1576–83.PubMedPubMedCentralCrossRefGoogle Scholar
  16. Benhamou PY, Milliat-Guittard L, et al. Quality of life after islet transplantation: data from the GRAGIL 1 and 2 trials. Diabet Med. 2009;26(6):617–21.PubMedCrossRefGoogle Scholar
  17. Bergenstal RM, Tamborlane WV, et al. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med. 2010;363(4):311–20.PubMedCrossRefGoogle Scholar
  18. Bergenstal RM, Klonoff DC, et al. Threshold-based insulin-pump interruption for reduction of hypoglycemia. N Engl J Med. 2013;369(3):224–32.PubMedCrossRefGoogle Scholar
  19. Berney T, Johnson PR. Donor pancreata: evolving approaches to organ allocation for whole pancreas versus islet transplantation. Transplantation. 2010;90(3):238–43.PubMedCrossRefGoogle Scholar
  20. Bertuzzi F, Ricordi C. Beta-cell replacement in immunosuppressed recipients: old and new clinical indications. Acta Diabetol. 2007;44(4):171–6.PubMedCrossRefGoogle Scholar
  21. Bertuzzi F, Verzaro R, et al. Brittle type 1 diabetes mellitus. Curr Med Chem. 2007;14(16):1739–44.PubMedCrossRefGoogle Scholar
  22. Bhargava R, Senior PA, et al. Prevalence of hepatic steatosis after islet transplantation and its relation to graft function. Diabetes. 2004;53(5):1311–7.PubMedCrossRefGoogle Scholar
  23. Biesenbach G, Konigsrainer A, et al. Progression of macrovascular diseases is reduced in type 1 diabetic patients after more than 5 years successful combined pancreas-kidney transplantation in comparison to kidney transplantation alone. Transpl Int. 2005;18(9):1054–60.PubMedCrossRefGoogle Scholar
  24. Bode BW, Schwartz S, et al. Glycemic characteristics in continuously monitored patients with type 1 and type 2 diabetes: normative values. Diabetes Care. 2005;28(10):2361–6.PubMedCrossRefGoogle Scholar
  25. Boggi U, Vistoli F, et al. Results of pancreas transplantation alone with special attention to native kidney function and proteinuria in type 1 diabetes patients. Rev Diabet Stud. 2011;8(2):259–67.PubMedPubMedCentralCrossRefGoogle Scholar
  26. Bonfanti R, Lepore G, et al. Survey on the use of insulin pumps in Italy: comparison between pediatric and adult age groups (IMITA study). Acta Diabetol. 2015;53:403.PubMedCrossRefGoogle Scholar
  27. Bretzel R, Brendel M, Hering B. International islet transplant registry. Newsletter #9. 2001;8:1.Google Scholar
  28. Campbell PM, Salam A, et al. Pretransplant HLA antibodies are associated with reduced graft survival after clinical islet transplantation. Am J Transplant. 2007;7(5):1242–8.PubMedCrossRefGoogle Scholar
  29. Campistol JM, de Fijter JW, et al. mTOR inhibitor-associated dermatologic and mucosal problems. Clin Transpl. 2010;24(2):149–56.CrossRefGoogle Scholar
  30. Cantarelli E, Piemonti L. Alternative transplantation sites for pancreatic islet grafts. Curr Diab Rep. 2011;11(5):364–74.CrossRefPubMedGoogle Scholar
  31. Cartwright A, Wallymahmed M, et al. The outcome of brittle type 1 diabetes – a 20 year study. QJM. 2011;104(7):575–9.PubMedCrossRefGoogle Scholar
  32. Casey JJ, Lakey JR, et al. Portal venous pressure changes after sequential clinical islet transplantation. Transplantation. 2002;74(7):913–5.PubMedCrossRefGoogle Scholar
  33. Chiang JL, Kirkman MS, et al. Type 1 diabetes through the life span: a position statement of the American diabetes association. Diabetes Care. 2014;37(7):2034–54.PubMedPubMedCentralCrossRefGoogle Scholar
  34. Choudhary P, Geddes J, et al. Frequency of biochemical hypoglycaemia in adults with Type 1 diabetes with and without impaired awareness of hypoglycaemia: no identifiable differences using continuous glucose monitoring. Diabet Med. 2010;27(6):666–72.PubMedCrossRefGoogle Scholar
  35. Choudhary P, Rickels MR, et al. Evidence-informed clinical practice recommendations for treatment of type 1 diabetes complicated by problematic hypoglycemia. Diabetes Care. 2015;38(6):1016–29.PubMedPubMedCentralCrossRefGoogle Scholar
  36. Citro A, Cantarelli E, et al. CXCR1/2 inhibition enhances pancreatic islet survival after transplantation. J Clin Invest. 2012;122(10):3647–51.PubMedPubMedCentralCrossRefGoogle Scholar
  37. Citro A, Cantarelli E, et al. Anti-inflammatory strategies to enhance islet engraftment and survival. Curr Diab Rep. 2013;13(5):733–44.PubMedCrossRefGoogle Scholar
  38. Citro A, Cantarelli E, et al. The CXCR1/2 pathway: involvement in diabetes pathophysiology and potential target for T1D interventions. Curr Diab Rep. 2015;15(10):638.CrossRefGoogle Scholar
  39. Clarke WL, Cox DJ, et al. Reduced awareness of hypoglycemia in adults with IDDM. A prospective study of hypoglycemic frequency and associated symptoms. Diabetes Care. 1995;18(4):517–22.PubMedCrossRefGoogle Scholar
  40. Cook K, Sollinger HW, et al. Pancreaticocystostomy: an alternative method for exocrine drainage of segmental pancreatic allografts. Transplantation. 1983;35(6):634–6.PubMedCrossRefGoogle Scholar
  41. Coppelli A, Giannarelli R, et al. Pancreas transplant alone determines early improvement of cardiovascular risk factors and cardiac function in type 1 diabetic patients. Transplantation. 2003;76(6):974–6.PubMedCrossRefGoogle Scholar
  42. Cryer PE. Mechanisms of hypoglycemia-associated autonomic failure in diabetes. N Engl J Med. 2013;369(4):362–72.PubMedCrossRefGoogle Scholar
  43. Cure P, Pileggi A, et al. Improved metabolic control and quality of life in seven patients with type 1 diabetes following islet after kidney transplantation. Transplantation. 2008;85(6):801–12.PubMedCrossRefGoogle Scholar
  44. D’Addio F, Maffi P, et al. Islet transplantation stabilizes hemostatic abnormalities and cerebral metabolism in individuals with type 1 diabetes. Diabetes Care. 2014;37(1):267–76.PubMedCrossRefGoogle Scholar
  45. Danielson KK, Hatipoglu B, et al. Reduction in carotid intima-media thickness after pancreatic islet transplantation in patients with type 1 diabetes. Diabetes Care. 2013;36(2):450–6.PubMedPubMedCentralCrossRefGoogle Scholar
  46. de Mattos AM, Olyaei AJ, et al. Nephrotoxicity of immunosuppressive drugs: long-term consequences and challenges for the future. Am J Kidney Dis. 2000;35(2):333–46.PubMedCrossRefGoogle Scholar
  47. Del Carro U, Fiorina P, et al. Evaluation of polyneuropathy markers in type 1 diabetic kidney transplant patients and effects of islet transplantation: neurophysiological and skin biopsy longitudinal analysis. Diabetes Care. 2007;30(12):3063–9.PubMedCrossRefGoogle Scholar
  48. Dew MA, Switzer GE, et al. Psychosocial assessments and outcomes in organ transplantation. Prog Transplant. 2000;10(4):239–59; quiz 260–231.PubMedCrossRefGoogle Scholar
  49. Dieterle CD, Arbogast H, et al. Metabolic follow-up after long-term pancreas graft survival. Eur J Endocrinol. 2007;156(5):603–10.PubMedCrossRefGoogle Scholar
  50. Dubernard JM, Traeger J, et al. A new method of preparation of segmental pancreatic grafts for transplantation: trials in dogs and in man. Surgery. 1978;84(5):633–9.PubMedGoogle Scholar
  51. Fatourechi MM, Kudva YC, et al. Clinical review: hypoglycemia with intensive insulin therapy: a systematic review and meta-analyses of randomized trials of continuous subcutaneous insulin infusion versus multiple daily injections. J Clin Endocrinol Metab. 2009;94(3):729–40.PubMedCrossRefGoogle Scholar
  52. Feldmeyer L, Hofbauer GF, et al. Mammalian target of rapamycin (mTOR) inhibitors slow skin carcinogenesis, but impair wound healing. Br J Dermatol. 2012;166(2):422–4.PubMedCrossRefGoogle Scholar
  53. Feltbower RG, Bodansky HJ, et al. Acute complications and drug misuse are important causes of death for children and young adults with type 1 diabetes: results from the Yorkshire register of diabetes in children and young adults. Diabetes Care. 2008;31(5):922–6.PubMedCrossRefGoogle Scholar
  54. Fioretto P, Steffes MW, et al. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med. 1998;339(2):69–75.PubMedCrossRefGoogle Scholar
  55. Fioretto P, Sutherland DE, et al. Remodeling of renal interstitial and tubular lesions in pancreas transplant recipients. Kidney Int. 2006;69(5):907–12.PubMedCrossRefGoogle Scholar
  56. Fiorina P, La Rocca E, et al. Reversal of left ventricular diastolic dysfunction after kidney-pancreas transplantation in type 1 diabetic uremic patients. Diabetes Care. 2000;23(12):1804–10.PubMedCrossRefGoogle Scholar
  57. Fiorina P, Folli F, et al. Long-term beneficial effect of islet transplantation on diabetic macro-/microangiopathy in type 1 diabetic kidney-transplanted patients. Diabetes Care. 2003a;26(4):1129–36.PubMedCrossRefGoogle Scholar
  58. Fiorina P, Folli F, et al. Islet transplantation improves vascular diabetic complications in patients with diabetes who underwent kidney transplantation: a comparison between kidney-pancreas and kidney-alone transplantation. Transplantation. 2003b;75(8):1296–301.PubMedCrossRefGoogle Scholar
  59. Fiorina P, Folli F, et al. Islet transplantation is associated with improvement of renal function among uremic patients with type I diabetes mellitus and kidney transplants. J Am Soc Nephrol. 2003c;14(8):2150–8.PubMedCrossRefGoogle Scholar
  60. Fiorina P, Gremizzi C, et al. Islet transplantation is associated with an improvement of cardiovascular function in type 1 diabetic kidney transplant patients. Diabetes Care. 2005a;28(6):1358–65.PubMedCrossRefGoogle Scholar
  61. Fiorina P, Venturini M, et al. Natural history of kidney graft survival, hypertrophy, and vascular function in end-stage renal disease type 1 diabetic kidney-transplanted patients: beneficial impact of pancreas and successful islet cotransplantation. Diabetes Care. 2005b;28(6):1303–10.PubMedCrossRefGoogle Scholar
  62. Fiorina P, Perseghin G, et al. Altered kidney graft high-energy phosphate metabolism in kidney-transplanted end-stage renal disease type 1 diabetic patients: a cross-sectional analysis of the effect of kidney alone and kidney-pancreas transplantation. Diabetes Care. 2007;30(3):597–603.PubMedCrossRefGoogle Scholar
  63. Fiorina P, Vezzulli P, et al. Near normalization of metabolic and functional features of the central nervous system in type 1 diabetic patients with end-stage renal disease after kidney-pancreas transplantation. Diabetes Care. 2012;35(2):367–74.PubMedPubMedCentralCrossRefGoogle Scholar
  64. Floyd B, Chandra P, et al. Comparative analysis of the efficacy of continuous glucose monitoring and self-monitoring of blood glucose in type 1 diabetes mellitus. J Diabetes Sci Technol. 2012;6(5):1094–102.PubMedPubMedCentralCrossRefGoogle Scholar
  65. Folli F, Guzzi V, et al. Proteomics reveals novel oxidative and glycolytic mechanisms in type 1 diabetic patients’ skin which are normalized by kidney-pancreas transplantation. PLoS One. 2010;5(3):e9923.PubMedPubMedCentralCrossRefGoogle Scholar
  66. Fotino C, Pileggi A. Blockade of leukocyte function antigen-1 (LFA-1) in clinical islet transplantation. Curr Diab Rep. 2011;11(5):337–44.PubMedCrossRefGoogle Scholar
  67. Franco OH, Steyerberg EW, et al. Associations of diabetes mellitus with total life expectancy and life expectancy with and without cardiovascular disease. Arch Intern Med. 2007;167(11):1145–51.PubMedCrossRefGoogle Scholar
  68. Frank AM, Barker CF, et al. Comparison of whole organ pancreas and isolated islet transplantation for type 1 diabetes. Adv Surg. 2005;39:137–63.PubMedCrossRefGoogle Scholar
  69. Freckmann G, Hagenlocher S, et al. Continuous glucose profiles in healthy subjects under everyday life conditions and after different meals. J Diabetes Sci Technol. 2007;1(5):695–703.PubMedPubMedCentralCrossRefGoogle Scholar
  70. Frier BM. Morbidity of hypoglycemia in type 1 diabetes. Diabetes Res Clin Pract. 2004;65(Suppl 1):S47–52.PubMedCrossRefGoogle Scholar
  71. Frier BM. Hypoglycaemia in diabetes mellitus: epidemiology and clinical implications. Nat Rev Endocrinol. 2014;10(12):711–22.PubMedCrossRefGoogle Scholar
  72. Froud T, Yrizarry JM, et al. Use of D-STAT to prevent bleeding following percutaneous transhepatic intraportal islet transplantation. Cell Transplant. 2004;13(1):55–9.PubMedCrossRefGoogle Scholar
  73. Froud T, Ricordi C, et al. Islet transplantation in type 1 diabetes mellitus using cultured islets and steroid-free immunosuppression: Miami experience. Am J Transplant. 2005;5(8):2037–46.PubMedCrossRefGoogle Scholar
  74. Froud T, Baidal DA, et al. Islet transplantation with alemtuzumab induction and calcineurin-free maintenance immunosuppression results in improved short- and long-term outcomes. Transplantation. 2008;86(12):1695–701.PubMedPubMedCentralCrossRefGoogle Scholar
  75. Fung MA, Warnock GL, et al. The effect of medical therapy and islet cell transplantation on diabetic nephropathy: an interim report. Transplantation. 2007;84(1):17–22.PubMedCrossRefGoogle Scholar
  76. Gaba RC, Garcia-Roca R, et al. Pancreatic islet cell transplantation: an update for interventional radiologists. J Vasc Interv Radiol. 2012;23(5):583–94; quiz 594.PubMedCrossRefGoogle Scholar
  77. Gaber AO, Oxley D, et al. Changes in gastric emptying in recipients of successful combined pancreas-kidney transplants. Dig Dis. 1991;9(6):437–43.PubMedCrossRefGoogle Scholar
  78. Gaber AO, el-Gebely S, et al. Early improvement in cardiac function occurs for pancreas-kidney but not diabetic kidney-alone transplant recipients. Transplantation. 1995a;59(8):1105–12.PubMedCrossRefGoogle Scholar
  79. Gaber AO, Shokouh-Amiri MH, et al. Results of pancreas transplantation with portal venous and enteric drainage. Ann Surg. 1995b;221(6):613–22; discussion 622–614.PubMedPubMedCentralCrossRefGoogle Scholar
  80. Gala-Lopez BL, Senior PA, et al. Late cytomegalovirus transmission and impact of T-depletion in clinical islet transplantation. Am J Transplant. 2011;11(12):2708–14.PubMedCrossRefGoogle Scholar
  81. Garg S, Zisser H, et al. Improvement in glycemic excursions with a transcutaneous, real-time continuous glucose sensor: a randomized controlled trial. Diabetes Care. 2006;29(1):44–50.PubMedCrossRefGoogle Scholar
  82. Geddes J, Schopman JE, et al. Prevalence of impaired awareness of hypoglycaemia in adults with type 1 diabetes. Diabet Med. 2008;25(4):501–4.PubMedCrossRefGoogle Scholar
  83. Geissler EK. Post-transplantation malignancies: here today, gone tomorrow? Nat Rev Clin Oncol. 2015;12(12):705–17.PubMedCrossRefGoogle Scholar
  84. Gerber PA, Pavlicek V, et al. Simultaneous islet-kidney vs pancreas-kidney transplantation in type 1 diabetes mellitus: a 5 year single centre follow-up. Diabetologia. 2008;51(1):110–9.PubMedCrossRefGoogle Scholar
  85. Giannarelli R, Coppelli A, et al. Effects of pancreas-kidney transplantation on diabetic retinopathy. Transpl Int. 2005;18(5):619–22.PubMedCrossRefGoogle Scholar
  86. Giannarelli R, Coppelli A, et al. Pancreas transplant alone has beneficial effects on retinopathy in type 1 diabetic patients. Diabetologia. 2006;49(12):2977–82.PubMedCrossRefGoogle Scholar
  87. Gill GV. The spectrum of brittle diabetes. J R Soc Med. 1992;85(5):259–61.PubMedPubMedCentralGoogle Scholar
  88. Gill GV, Lucas S, et al. Prevalence and characteristics of brittle diabetes in Britain. QJM. 1996;89(11):839–43.PubMedCrossRefGoogle Scholar
  89. Gillard P, Rustandi M, et al. Early alteration of kidney function in nonuremic type 1 diabetic islet transplant recipients under tacrolimus-mycophenolate therapy. Transplantation. 2014;98:451.PubMedCrossRefGoogle Scholar
  90. Giorda CB, Ozzello A, et al. Incidence and risk factors for severe and symptomatic hypoglycemia in type 1 diabetes. Results of the HYPOS-1 study. Acta Diabetol. 2015;52(5):845–53.PubMedCrossRefGoogle Scholar
  91. Girman P, Lipar K, et al. Neoplasm incidence in simultaneous pancreas and kidney transplantation: a single-center analysis. Transplant Proc. 2011;43(9):3288–91.PubMedCrossRefGoogle Scholar
  92. Gliedman ML, Gold M, et al. Clinical segmental pancreatic transplantation with ureter-pancreatic duct anastomosis for exocrine drainage. Surgery. 1973;74(2):171–80.PubMedGoogle Scholar
  93. Gold AE, MacLeod KM, et al. Frequency of severe hypoglycemia in patients with type I diabetes with impaired awareness of hypoglycemia. Diabetes Care. 1994;17(7):697–703.PubMedCrossRefGoogle Scholar
  94. Golden SH, Sapir T. Methods for insulin delivery and glucose monitoring in diabetes: summary of a comparative effectiveness review. J Manag Care Pharm. 2012;18(6 Suppl):S1–17.PubMedGoogle Scholar
  95. Graveling AJ, Frier BM. Impaired awareness of hypoglycaemia: a review. Diabetes Metab. 2010;36(Suppl 3):S64–74.PubMedCrossRefGoogle Scholar
  96. Gregg EW, Li Y, et al. Changes in diabetes-related complications in the United States, 1990–2010. N Engl J Med. 2014;370(16):1514–23.PubMedCrossRefGoogle Scholar
  97. Gross CR, Zehrer CL. Health-related quality of life outcomes of pancreas transplant recipients. Clin Transpl. 1992;6(3 part 1):165–71.Google Scholar
  98. Gruden G, Barutta F, et al. Severe hypoglycemia and cardiovascular disease incidence in type 1 diabetes: the EURODIAB prospective complications study. Diabetes Care. 2012;35(7):1598–604.PubMedPubMedCentralCrossRefGoogle Scholar
  99. Gruessner AC. 2011 update on pancreas transplantation: comprehensive trend analysis of 25,000 cases followed up over the course of twenty-four years at the international pancreas transplant registry (IPTR). Rev Diabet Stud. 2011;8(1):6–16.PubMedPubMedCentralCrossRefGoogle Scholar
  100. Gruessner AC, Gruessner RW. Pancreas transplant outcomes for United States and non United States cases as reported to the united network for organ sharing and the international pancreas transplant registry as of December 2011. Clin Transpl. 2012:23–40. PMID: 23721008.Google Scholar
  101. Gruessner RW, Gruessner AC. The current state of pancreas transplantation. Nat Rev Endocrinol. 2013a;9(9):555–62.PubMedCrossRefGoogle Scholar
  102. Gruessner RW, Gruessner AC. Pancreas transplant alone: a procedure coming of age. Diabetes Care. 2013b;36(8):2440–7.PubMedPubMedCentralCrossRefGoogle Scholar
  103. Gruessner AC, Gruessner RW. Declining numbers of pancreas transplantations but significant improvements in outcome. Transplant Proc. 2014;46(6):1936–7.PubMedCrossRefGoogle Scholar
  104. Gruessner AC, Sutherland DE. Pancreas transplant outcomes for United States (US) cases reported to the united network for organ sharing (UNOS) and non-US cases reported to the international pancreas transplant registry (IPTR) as of October, 2000. Clin Transpl. 2000:45–72. PMID: 11512358.Google Scholar
  105. Gruessner RW, Sutherland DE, et al. Mortality assessment for pancreas transplants. Am J Transplant. 2004;4(12):2018–26.PubMedCrossRefGoogle Scholar
  106. Han DJ, Sutherland DE. Pancreas transplantation. Gut Liver. 2010;4(4):450–65.PubMedPubMedCentralCrossRefGoogle Scholar
  107. Hansen A, Johansson BL, et al. C-peptide exerts beneficial effects on myocardial blood flow and function in patients with type 1 diabetes. Diabetes. 2002;51(10):3077–82.PubMedCrossRefGoogle Scholar
  108. Hao WJ, Zong HT, et al. The efficacy and safety of alemtuzumab and daclizumab versus antithymocyte globulin during organ transplantation: a meta-analysis. Transplant Proc. 2012;44(10):2955–60.PubMedCrossRefGoogle Scholar
  109. Hasskarl J. Everolimus. Recent Results Cancer Res. 2014;201:373–92.PubMedCrossRefGoogle Scholar
  110. Helfrich M, Ison MG. Opportunistic infections complicating solid organ transplantation with alemtuzumab induction. Transpl Infect Dis. 2015;17(5):627–36.PubMedCrossRefGoogle Scholar
  111. Hering BJ, Bretzel RG, et al. New protocol toward prevention of early human islet allograft failure. Transplant Proc. 1994;26(2):570–1.PubMedGoogle Scholar
  112. Hering BJ, Kandaswamy R, et al. Single-donor, marginal-dose islet transplantation in patients with type 1 diabetes. JAMA. 2005;293(7):830–5.PubMedCrossRefGoogle Scholar
  113. Hilbrands R, Huurman VA, et al. Differences in baseline lymphocyte counts and autoreactivity are associated with differences in outcome of islet cell transplantation in type 1 diabetic patients. Diabetes. 2009;58(10):2267–76.PubMedPubMedCentralCrossRefGoogle Scholar
  114. Hoi-Hansen T, Pedersen-Bjergaard U, et al. Classification of hypoglycemia awareness in people with type 1 diabetes in clinical practice. J Diabetes Complicat. 2010;24(6):392–7.PubMedCrossRefGoogle Scholar
  115. Hopkins D, Lawrence I, et al. Improved biomedical and psychological outcomes 1 year after structured education in flexible insulin therapy for people with type 1 diabetes: the U.K. DAFNE experience. Diabetes Care. 2012;35(8):1638–42.PubMedPubMedCentralCrossRefGoogle Scholar
  116. Hu FB, Stampfer MJ, et al. The impact of diabetes mellitus on mortality from all causes and coronary heart disease in women: 20 years of follow-up. Arch Intern Med. 2001;161(14):1717–23.PubMedCrossRefGoogle Scholar
  117. Isla Pera P, Moncho Vasallo J, et al. Quality of life in simultaneous pancreas-kidney transplant recipients. Clin Transpl. 2009;23(5):600–5.CrossRefGoogle Scholar
  118. Jahansouz C, Kumer SC, et al. Evolution of beta-cell replacement therapy in diabetes mellitus: pancreas transplantation. Diabetes Technol Ther. 2011;13(3):395–418.PubMedCrossRefGoogle Scholar
  119. Johnson PR, Jones KE. Pancreatic islet transplantation. Semin Pediatr Surg. 2012;21(3):272–80.  https://doi.org/10.1053/j.sempedsurg.2012.05.012. PMID: 22800980 [Indexed for MEDLINE]PubMedCrossRefGoogle Scholar
  120. Johnson JA, Kotovych M, et al. Reduced fear of hypoglycemia in successful islet transplantation. Diabetes Care. 2004;27(2):624–5.PubMedCrossRefGoogle Scholar
  121. Johnston O, Rose CL, et al. Sirolimus is associated with new-onset diabetes in kidney transplant recipients. J Am Soc Nephrol. 2008;19(7):1411–8.PubMedPubMedCentralCrossRefGoogle Scholar
  122. Jukema JW, Smets YF, et al. Impact of simultaneous pancreas and kidney transplantation on progression of coronary atherosclerosis in patients with end-stage renal failure due to type 1 diabetes. Diabetes Care. 2002;25(5):906–11.PubMedCrossRefGoogle Scholar
  123. Kandaswamy R, Skeans MA, et al. OPTN/SRTR 2013 annual data report: pancreas. Am J Transplant. 2015;15(Suppl 2):1–20.PubMedCrossRefGoogle Scholar
  124. Kandaswamy R, Skeans MA, et al. Pancreas. Am J Transplant. 2016;16(Suppl 2):47–68.PubMedCrossRefGoogle Scholar
  125. Kelly WD, Lillehei RC, et al. Allotransplantation of the pancreas and duodenum along with the kidney in diabetic nephropathy. Surgery. 1967;61(6):827–37.PubMedGoogle Scholar
  126. Kennedy WR, Navarro X, et al. Effects of pancreatic transplantation on diabetic neuropathy. N Engl J Med. 1990;322(15):1031–7.PubMedCrossRefGoogle Scholar
  127. Kent LA, Gill GV, et al. Mortality and outcome of patients with brittle diabetes and recurrent ketoacidosis. Lancet. 1994;344(8925):778–81.PubMedCrossRefGoogle Scholar
  128. Kleinclauss F, Fauda M, et al. Pancreas after living donor kidney transplants in diabetic patients: impact on long-term kidney graft function. Clin Transpl. 2009;23(4):437–46.CrossRefGoogle Scholar
  129. Kovatchev BP, Cox DJ, et al. Assessment of risk for severe hypoglycemia among adults with IDDM: validation of the low blood glucose index. Diabetes Care. 1998;21(11):1870–5.PubMedCrossRefGoogle Scholar
  130. Koznarova R, Saudek F, et al. Beneficial effect of pancreas and kidney transplantation on advanced diabetic retinopathy. Cell Transplant. 2000;9(6):903–8.PubMedCrossRefGoogle Scholar
  131. Kroon E, Martinson LA, et al. Pancreatic endoderm derived from human embryonic stem cells generates glucose-responsive insulin-secreting cells in vivo. Nat Biotechnol. 2008;26(4):443–52.PubMedCrossRefGoogle Scholar
  132. La Rocca E, Minicucci F, et al. Evolution of carotid vascular lesions in kidney-pancreas and kidney-alone transplanted insulin-dependent diabetic patients. Transplant Proc. 1995;27(6):3072.PubMedGoogle Scholar
  133. La Rocca E, Fiorina P, et al. Cardiovascular outcomes after kidney-pancreas and kidney-alone transplantation. Kidney Int. 2001;60(5):1964–71.PubMedCrossRefGoogle Scholar
  134. Larsen JL, Ratanasuwan T, et al. Carotid intima media thickness decreases after pancreas transplantation. Transplantation. 2002;73(6):936–40.PubMedCrossRefGoogle Scholar
  135. Larsen JL, Colling CW, et al. Pancreas transplantation improves vascular disease in patients with type 1 diabetes. Diabetes Care. 2004;27(7):1706–11.PubMedCrossRefGoogle Scholar
  136. Larsen CP, Pearson TC, et al. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant. 2005;5(3):443–53.PubMedCrossRefGoogle Scholar
  137. Lee TC, Barshes NR, et al. The effect of pancreatic islet transplantation on progression of diabetic retinopathy and neuropathy. Transplant Proc. 2005;37(5):2263–5.PubMedCrossRefGoogle Scholar
  138. Lehmann R, Graziano J, et al. Glycemic control in simultaneous islet-kidney versus pancreas-kidney transplantation in type 1 diabetes: a prospective 13-year follow-up. Diabetes Care. 2015;38(5):752–9.PubMedCrossRefGoogle Scholar
  139. Leitao CB, Tharavanij T, et al. Restoration of hypoglycemia awareness after islet transplantation. Diabetes Care. 2008;31(11):2113–5.PubMedPubMedCentralCrossRefGoogle Scholar
  140. Leitao CB, Cure P, et al. Stable renal function after islet transplantation: importance of patient selection and aggressive clinical management. Transplantation. 2009;87(5):681–8.PubMedPubMedCentralCrossRefGoogle Scholar
  141. Letavernier E, Legendre C. mToR inhibitors-induced proteinuria: mechanisms, significance, and management. Transplant Rev (Orlando). 2008;22(2):125–30.CrossRefGoogle Scholar
  142. Li T, Ma R, et al. PD-1/PD-L1 costimulatory pathway-induced mouse islet transplantation immune tolerance. Transplant Proc. 2015;47(1):165–70.PubMedCrossRefGoogle Scholar
  143. Lind M, Svensson AM, et al. Glycemic control and excess mortality in type 1 diabetes. N Engl J Med. 2014;371(21):1972–82.PubMedCrossRefGoogle Scholar
  144. Livingstone SJ, Levin D, et al. Estimated life expectancy in a Scottish cohort with type 1 diabetes, 2008–2010. JAMA. 2015;313(1):37–44.PubMedPubMedCentralCrossRefGoogle Scholar
  145. Lo JF, Wang Y, et al. Quantitative and temporal control of oxygen microenvironment at the single islet level. J Vis Exp. 2013;(81):e50616.  https://doi.org/10.3791/50616.
  146. Maahs DM, Calhoun P, et al. A randomized trial of a home system to reduce nocturnal hypoglycemia in type 1 diabetes. Diabetes Care. 2014;37(7):1885–91.PubMedPubMedCentralCrossRefGoogle Scholar
  147. Maffi P, Angeli E, et al. Minimal focal steatosis of liver after islet transplantation in humans: a long-term study. Cell Transplant. 2005;14(10):727–33.PubMedCrossRefGoogle Scholar
  148. Maffi P, Bertuzzi F, et al. Kidney function after islet transplant alone in type 1 diabetes: impact of immunosuppressive therapy on progression of diabetic nephropathy. Diabetes Care. 2007;30(5):1150–5.PubMedCrossRefGoogle Scholar
  149. Maffi P, Scavini M, et al. Risks and benefits of transplantation in the cure of type 1 diabetes: whole pancreas versus islet transplantation. A single center study. Rev Diabet Stud. 2011;8(1):44–50.PubMedPubMedCentralCrossRefGoogle Scholar
  150. Maffi P, Berney T, et al. Calcineurin inhibitor-free immunosuppressive regimen in type 1 diabetes patients receiving islet transplantation: single-group phase 1/2 trial. Transplantation. 2014;98(12):1301–9.PubMedCrossRefGoogle Scholar
  151. Mannucci E, Monami M, et al. Achieving HbA1c targets in clinical trials and in the real world: a systematic review and meta-analysis. J Endocrinol Investig. 2014;37(5):477–95.CrossRefGoogle Scholar
  152. Marigliano M, Bertera S, et al. Pig-to-nonhuman primates pancreatic islet xenotransplantation: an overview. Curr Diab Rep. 2011;11(5):402–12.PubMedPubMedCentralCrossRefGoogle Scholar
  153. Markmann JF. Isolated pancreatic islet transplantation: a coming of age. Am J Transplant. 2016;16(2):381–2.PubMedCrossRefGoogle Scholar
  154. Martinenghi S, Comi G, et al. Amelioration of nerve conduction velocity following simultaneous kidney/pancreas transplantation is due to the glycaemic control provided by the pancreas. Diabetologia. 1997;40(9):1110–2.PubMedCrossRefGoogle Scholar
  155. Marzorati S, Pileggi A, et al. Allogeneic islet transplantation. Expert Opin Biol Ther. 2007;7(11):1627–45.PubMedCrossRefGoogle Scholar
  156. Matsuoka N, Itoh T, et al. High-mobility group box 1 is involved in the initial events of early loss of transplanted islets in mice. J Clin Invest. 2010;120(3):735–43.PubMedPubMedCentralCrossRefGoogle Scholar
  157. McAlister VC, Gao Z, et al. Sirolimus-tacrolimus combination immunosuppression. Lancet. 2000;355(9201):376–7.PubMedCrossRefGoogle Scholar
  158. McCoy RG, Van Houten HK, et al. Increased mortality of patients with diabetes reporting severe hypoglycemia. Diabetes Care. 2012;35(9):1897–901.PubMedPubMedCentralCrossRefGoogle Scholar
  159. McDonnell CM, Donath SM, et al. A novel approach to continuous glucose analysis utilizing glycemic variation. Diabetes Technol Ther. 2005;7(2):253–63.PubMedCrossRefGoogle Scholar
  160. McKnight JA, Wild SH, et al. Glycaemic control of type 1 diabetes in clinical practice early in the 21st century: an international comparison. Diabet Med. 2015;32(8):1036–50.PubMedCrossRefGoogle Scholar
  161. Merkel FK, Ryan WG, et al. Pancreatic transplantation for diabetes mellitus. IMJ Ill Med J. 1973;144(5):477–9 passim.Google Scholar
  162. Miller KM, Foster NC, et al. Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D exchange clinic registry. Diabetes Care. 2015;38(6):971–8.PubMedCrossRefGoogle Scholar
  163. Mittal S, Gough SC. Pancreas transplantation: a treatment option for people with diabetes. Diabet Med. 2014;31(5):512–21.PubMedCrossRefGoogle Scholar
  164. Mittal S, Johnson P, et al. Pancreas transplantation: solid organ and islet. Cold Spring Harb Perspect Med. 2014;4(4):a015610.PubMedPubMedCentralCrossRefGoogle Scholar
  165. Moassesfar S, Masharani U, et al. A comparative analysis of the safety, efficacy, and cost of islet versus pancreas transplantation in nonuremic patients with type 1 diabetes. Am J Transplant. 2016;16(2):518–26.PubMedCrossRefGoogle Scholar
  166. Moberg L, Johansson H, et al. Production of tissue factor by pancreatic islet cells as a trigger of detrimental thrombotic reactions in clinical islet transplantation. Lancet. 2002;360(9350):2039–45.PubMedCrossRefGoogle Scholar
  167. Mohan P, Safi K, et al. Improved patient survival in recipients of simultaneous pancreas-kidney transplant compared with kidney transplant alone in patients with type 1 diabetes mellitus and end-stage renal disease. Br J Surg. 2003;90(9):1137–41.PubMedCrossRefGoogle Scholar
  168. Morath C, Zeier M, et al. Metabolic control improves long-term renal allograft and patient survival in type 1 diabetes. J Am Soc Nephrol. 2008;19(8):1557–63.PubMedPubMedCentralCrossRefGoogle Scholar
  169. Morrissey PE, Shaffer D, et al. Peripheral vascular disease after kidney-pancreas transplantation in diabetic patients with end-stage renal disease. Arch Surg. 1997;132(4):358–61; discussion 361–352.PubMedCrossRefGoogle Scholar
  170. Mujtaba MA, Sharfuddin AA, et al. Conversion from tacrolimus to belatacept to prevent the progression of chronic kidney disease in pancreas transplantation: case report of two patients. Am J Transplant. 2014;14(11):2657–61.PubMedCrossRefGoogle Scholar
  171. Nakache R, Tyden G, et al. Long-term quality of life in diabetic patients after combined pancreas-kidney transplantation or kidney transplantation. Transplant Proc. 1994;26(2):510–1.PubMedGoogle Scholar
  172. Nano R, Clissi B, et al. Islet isolation for allotransplantation: variables associated with successful islet yield and graft function. Diabetologia. 2005;48(5):906–12.PubMedCrossRefGoogle Scholar
  173. Nath DS, Gruessner A, et al. Late anastomotic leaks in pancreas transplant recipients – clinical characteristics and predisposing factors. Clin Transpl. 2005;19(2):220–4.CrossRefGoogle Scholar
  174. Navarro X, Sutherland DE, et al. Long-term effects of pancreatic transplantation on diabetic neuropathy. Ann Neurol. 1997;42(5):727–36.PubMedCrossRefGoogle Scholar
  175. Nghiem DD, Corry RJ. Technique of simultaneous renal pancreatoduodenal transplantation with urinary drainage of pancreatic secretion. Am J Surg. 1987;153(4):405–6.PubMedCrossRefGoogle Scholar
  176. Nijhoff MF, Engelse MA, et al. Glycemic stability through islet-after-kidney transplantation using an Alemtuzumab-based induction regimen and long-term triple-maintenance immunosuppression. Am J Transplant. 2015;16:246.PubMedCrossRefGoogle Scholar
  177. Norman SP, Kommareddi M, et al. Early pancreas graft failure is associated with inferior late clinical outcomes after simultaneous kidney-pancreas transplantation. Transplantation. 2011;92(7):796–801.PubMedCrossRefGoogle Scholar
  178. Ogundipe OO, Geddes J, et al. Impaired hypoglycaemia awareness and employment in people with type 1 diabetes. Occup Med (Lond). 2011;61(4):241–6.CrossRefGoogle Scholar
  179. Ojo AO, Meier-Kriesche HU, et al. The impact of simultaneous pancreas-kidney transplantation on long-term patient survival. Transplantation. 2001;71(1):82–90.PubMedCrossRefGoogle Scholar
  180. Olsen SE, Asvold BO, et al. Hypoglycaemia symptoms and impaired awareness of hypoglycaemia in adults with type 1 diabetes: the association with diabetes duration. Diabet Med. 2014;31(10):1210–7.PubMedCrossRefGoogle Scholar
  181. Pagliuca FW, Millman JR, et al. Generation of functional human pancreatic beta cells in vitro. Cell. 2014;159(2):428–39.PubMedPubMedCentralCrossRefGoogle Scholar
  182. Paty BW, Ryan EA, et al. Intrahepatic islet transplantation in type 1 diabetic patients does not restore hypoglycemic hormonal counterregulation or symptom recognition after insulin independence. Diabetes. 2002;51(12):3428–34.PubMedCrossRefGoogle Scholar
  183. Paty BW, Senior PA, et al. Assessment of glycemic control after islet transplantation using the continuous glucose monitor in insulin-independent versus insulin-requiring type 1 diabetes subjects. Diabetes Technol Ther. 2006;8(2):165–73.PubMedCrossRefGoogle Scholar
  184. Pedersen-Bjergaard U, Pramming S, et al. Recall of severe hypoglycaemia and self-estimated state of awareness in type 1 diabetes. Diabetes Metab Res Rev. 2003;19(3):232–40.PubMedCrossRefGoogle Scholar
  185. Pedersen-Bjergaard U, Pramming S, et al. Severe hypoglycaemia in 1076 adult patients with type 1 diabetes: influence of risk markers and selection. Diabetes Metab Res Rev. 2004;20(6):479–86.PubMedCrossRefGoogle Scholar
  186. Phillip M, Battelino T, et al. Nocturnal glucose control with an artificial pancreas at a diabetes camp. N Engl J Med. 2013;368(9):824–33.PubMedCrossRefGoogle Scholar
  187. Pickup JC, Sutton AJ. Severe hypoglycaemia and glycaemic control in type 1 diabetes: meta-analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion. Diabet Med. 2008;25(7):765–74.PubMedCrossRefGoogle Scholar
  188. Piemonti L, Pileggi A. 25 years of the Ricordi automated method for islet isolation. CellR4. 2013;1(1):e128.Google Scholar
  189. Piemonti L, Everly MJ, et al. Alloantibody and autoantibody monitoring predicts islet transplantation outcome in human type 1 diabetes. Diabetes. 2013;62(5):1656–64.PubMedPubMedCentralCrossRefGoogle Scholar
  190. Pileggi A, Ricordi C, et al. Twenty years of clinical islet transplantation at the Diabetes Research Institute – University of Miami. Clin Transpl. 2004:177–204.Google Scholar
  191. Poggioli R, Faradji RN, et al. Quality of life after islet transplantation. Am J Transplant. 2006;6(2):371–8.PubMedCrossRefGoogle Scholar
  192. Port FK, Wolfe RA, et al. Comparison of survival probabilities for dialysis patients vs cadaveric renal transplant recipients. JAMA. 1993;270(11):1339–43.PubMedCrossRefGoogle Scholar
  193. Posselt AM, Bellin MD, et al. Islet transplantation in type 1 diabetics using an immunosuppressive protocol based on the anti-LFA-1 antibody efalizumab. Am J Transplant. 2010a;10(8):1870–80.PubMedPubMedCentralCrossRefGoogle Scholar
  194. Posselt AM, Szot GL, et al. Islet transplantation in type 1 diabetic patients using calcineurin inhibitor-free immunosuppressive protocols based on T-cell adhesion or costimulation blockade. Transplantation. 2010b;90(12):1595–601.PubMedPubMedCentralCrossRefGoogle Scholar
  195. Pozza G, Traeger J, et al. Endocrine responses of type 1 (insulin-dependent) diabetic patients following successful pancreas transplantation. Diabetologia. 1983;24(4):244–8.PubMedCrossRefGoogle Scholar
  196. Prieto M, Sutherland DE, et al. Pancreas transplant results according to the technique of duct management: bladder versus enteric drainage. Surgery. 1987;102(4):680–91.PubMedGoogle Scholar
  197. Radosevich DM, Jevne R, et al. Comprehensive health assessment and five-yr follow-up of allogeneic islet transplant recipients. Clin Transpl. 2013;27(6):E715–24.CrossRefGoogle Scholar
  198. Ramsay RC, Goetz FC, et al. Progression of diabetic retinopathy after pancreas transplantation for insulin-dependent diabetes mellitus. N Engl J Med. 1988;318(4):208–14.PubMedCrossRefGoogle Scholar
  199. Rana A, Gruessner A, et al. Survival benefit of solid-organ transplant in the United States. JAMA Surg. 2015;150(3):252–9.PubMedCrossRefGoogle Scholar
  200. Rangel EB. Tacrolimus in pancreas transplant: a focus on toxicity, diabetogenic effect and drug-drug interactions. Expert Opin Drug Metab Toxicol. 2014;10(11):1585–605.PubMedCrossRefGoogle Scholar
  201. Rayhill SC, D’Alessandro AM, et al. Simultaneous pancreas-kidney transplantation and living related donor renal transplantation in patients with diabetes: is there a difference in survival? Ann Surg. 2000;231(3):417–23.PubMedPubMedCentralCrossRefGoogle Scholar
  202. Reddy KS, Stablein D, et al. Long-term survival following simultaneous kidney-pancreas transplantation versus kidney transplantation alone in patients with type 1 diabetes mellitus and renal failure. Am J Kidney Dis. 2003;41(2):464–70.PubMedCrossRefGoogle Scholar
  203. Rezania A, Bruin JE, et al. Reversal of diabetes with insulin-producing cells derived in vitro from human pluripotent stem cells. Nat Biotechnol. 2014;32(11):1121–33.PubMedCrossRefGoogle Scholar
  204. Rickels MR. Recovery of endocrine function after islet and pancreas transplantation. Curr Diab Rep. 2012;12(5):587–96.PubMedPubMedCentralCrossRefGoogle Scholar
  205. Rickels MR, Schutta MH, et al. {beta}-cell function following human islet transplantation for type 1 diabetes. Diabetes. 2005a;54(1):100–6.PubMedCrossRefGoogle Scholar
  206. Rickels MR, Schutta MH, et al. Islet cell hormonal responses to hypoglycemia after human islet transplantation for type 1 diabetes. Diabetes. 2005b;54(11):3205–11.PubMedCrossRefGoogle Scholar
  207. Rickels MR, Naji A, et al. Acute insulin responses to glucose and arginine as predictors of beta-cell secretory capacity in human islet transplantation. Transplantation. 2007;84(10):1357–60.PubMedCrossRefGoogle Scholar
  208. Ricordi C. Islet transplantation: a brave new world. Diabetes. 2003;52(7):1595–603.PubMedCrossRefGoogle Scholar
  209. Ricordi C, Lacy PE, et al. Automated method for isolation of human pancreatic islets. Diabetes. 1988;37(4):413–20.PubMedCrossRefGoogle Scholar
  210. Ricordi C, Socci C, et al. Isolation of the elusive pig islet. Surgery. 1990;107(6):688–94.PubMedGoogle Scholar
  211. Ricordi C, Tzakis AG, et al. Human islet isolation and allotransplantation in 22 consecutive cases. Transplantation. 1992;53(2):407–14.PubMedPubMedCentralCrossRefGoogle Scholar
  212. Robertson RP. Islet transplantation a decade later and strategies for filling a half-full glass. Diabetes. 2010;59(6):1285–91.PubMedPubMedCentralCrossRefGoogle Scholar
  213. Robertson P, Davis C, et al. Pancreas transplantation in type 1 diabetes. Diabetes Care. 2004;27(Suppl 1):S105.PubMedGoogle Scholar
  214. Robertson RP, Davis C, et al. Pancreas and islet transplantation in type 1 diabetes. Diabetes Care. 2006;29(4):935.PubMedCrossRefGoogle Scholar
  215. Rosenlof LK, Earnhardt RC, et al. Pancreas transplantation. An initial experience with systemic and portal drainage of pancreatic allografts. Ann Surg. 1992;215(6):586–95; discussion 596–587.PubMedPubMedCentralCrossRefGoogle Scholar
  216. Ross PL, Milburn J, et al. Clinical review: insulin pump-associated adverse events in adults and children. Acta Diabetol. 2015;52(6):1017–24.PubMedCrossRefGoogle Scholar
  217. Rostambeigi N, Kudva YC, et al. Epidemiology of infections requiring hospitalization during long-term follow-up of pancreas transplantation. Transplantation. 2010;89(9):1126–33.PubMedCrossRefGoogle Scholar
  218. Russell SJ, El-Khatib FH, et al. Outpatient glycemic control with a bionic pancreas in type 1 diabetes. N Engl J Med. 2014;371(4):313–25.PubMedPubMedCentralCrossRefGoogle Scholar
  219. Ryan EA, Paty BW, et al. Risks and side effects of islet transplantation. Curr Diab Rep. 2004a;4(4):304–9.PubMedCrossRefGoogle Scholar
  220. Ryan EA, Shandro T, et al. Assessment of the severity of hypoglycemia and glycemic lability in type 1 diabetic subjects undergoing islet transplantation. Diabetes. 2004b;53(4):955–62.PubMedCrossRefGoogle Scholar
  221. Ryan EA, Paty BW, et al. Five-year follow-up after clinical islet transplantation. Diabetes. 2005;54(7):2060–9.PubMedCrossRefGoogle Scholar
  222. Salonia A, D’Addio F, et al. Kidney-pancreas transplantation is associated with near-normal sexual function in uremic type 1 diabetic patients. Transplantation. 2011;92(7):802–8.PubMedCrossRefGoogle Scholar
  223. Salvalaggio PR, Dzebisashvili N, et al. Incremental value of the pancreas allograft to the survival of simultaneous pancreas-kidney transplant recipients. Diabetes Care. 2009;32(4):600–2.PubMedPubMedCentralCrossRefGoogle Scholar
  224. Scharp DW, Lacy PE, et al. Insulin independence after islet transplantation into type I diabetic patient. Diabetes. 1990;39(4):515–8.PubMedCrossRefGoogle Scholar
  225. Schmidt S, Norgaard K. Bolus calculators. J Diabetes Sci Technol. 2014;8(5):1035–41.PubMedPubMedCentralCrossRefGoogle Scholar
  226. Schulz TC, Young HY, et al. A scalable system for production of functional pancreatic progenitors from human embryonic stem cells. PLoS One. 2012;7(5):e37004.PubMedPubMedCentralCrossRefGoogle Scholar
  227. Seaquist ER, Anderson J, et al. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care. 2013;36(5):1384–95.PubMedPubMedCentralCrossRefGoogle Scholar
  228. Secchi A, Socci C, et al. Islet transplantation in IDDM patients. Diabetologia. 1997;40(2):225–31.PubMedCrossRefGoogle Scholar
  229. Senior PA, Zeman M, et al. Changes in renal function after clinical islet transplantation: four-year observational study. Am J Transplant. 2007;7(1):91–8.PubMedCrossRefGoogle Scholar
  230. Shapiro AM. Strategies toward single-donor islets of Langerhans transplantation. Curr Opin Organ Transplant. 2011;16(6):627–31.PubMedPubMedCentralCrossRefGoogle Scholar
  231. Shapiro AM. Islet transplantation in type 1 diabetes: ongoing challenges, refined procedures, and long-term outcome. Rev Diabet Stud. 2012;9(4):385–406.PubMedCrossRefGoogle Scholar
  232. Shapiro AM, Lakey JR, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med. 2000;343(4):230–8.PubMedCrossRefGoogle Scholar
  233. Shapiro AM, Ricordi C, et al. Edmonton’s islet success has indeed been replicated elsewhere. Lancet. 2003;362(9391):1242.PubMedCrossRefGoogle Scholar
  234. Shapiro AM, Ricordi C, et al. International trial of the Edmonton protocol for islet transplantation. N Engl J Med. 2006;355(13):1318–30.PubMedCrossRefGoogle Scholar
  235. Shapiro AT, C, Imes S, Koh A, Kin T, O’Gorman D, Malcolm A, Dinyari P, Owen R, Kneteman RN, Bigam DL, Calne RY, Senior PA, Roep BO. Five-year results of islet-alone transplantation match pancreas-alone transplantation with Alemtuzumab, Tac/MMF, with strong suppression of auto and alloreactivity. In: 13th world congress of the international pancreas and islet transplant association (IPITA), Prague; 2011.Google Scholar
  236. Siskind E, Maloney C, et al. An analysis of pancreas transplantation outcomes based on age groupings – an update of the UNOS database. Clin Transpl. 2014;28(9):990–4.CrossRefGoogle Scholar
  237. Skrivarhaug T, Bangstad HJ, et al. Long-term mortality in a nationwide cohort of childhood-onset type 1 diabetic patients in Norway. Diabetologia. 2006;49(2):298–305.PubMedCrossRefGoogle Scholar
  238. Smets YF, Westendorp RG, et al. Effect of simultaneous pancreas-kidney transplantation on mortality of patients with type-1 diabetes mellitus and end-stage renal failure. Lancet. 1999;353(9168):1915–9.PubMedCrossRefGoogle Scholar
  239. Smith GC, Trauer T, et al. Prospective quality-of-life monitoring of simultaneous pancreas and kidney transplant recipients using the 36-item short form health survey. Am J Kidney Dis. 2010;55(4):698–707.PubMedCrossRefGoogle Scholar
  240. Socci C, Falqui L, et al. Fresh human islet transplantation to replace pancreatic endocrine function in type 1 diabetic patients. Report of six cases. Acta Diabetol. 1991;28(2):151–7.PubMedCrossRefGoogle Scholar
  241. Sollinger HW, Odorico JS, et al. One thousand simultaneous pancreas-kidney transplants at a single center with 22-year follow-up. Ann Surg. 2009;250(4):618–30.PubMedGoogle Scholar
  242. Speight J, Reaney MD, et al. Patient-reported outcomes following islet cell or pancreas transplantation (alone or after kidney) in type 1 diabetes: a systematic review. Diabet Med. 2010;27(7):812–22.PubMedCrossRefGoogle Scholar
  243. Stadler M, Anderwald C, et al. Chronic peripheral hyperinsulinemia in type 1 diabetic patients after successful combined pancreas-kidney transplantation does not affect ectopic lipid accumulation in skeletal muscle and liver. Diabetes. 2010;59(1):215–8.PubMedCrossRefGoogle Scholar
  244. Starzl TE, Iwatsuki S, et al. Pancreaticoduodenal transplantation in humans. Surg Gynecol Obstet. 1984;159(3):265–72.PubMedPubMedCentralGoogle Scholar
  245. Stratta RJ. Cardiovascular disease and neoplasms after pancreas transplantation. Lancet. 1998;352(9121):65–6.PubMedCrossRefGoogle Scholar
  246. Stratta RJ. Surgical nuances in pancreas transplantation. Transplant Proc. 2005;37(2):1291–3.PubMedCrossRefGoogle Scholar
  247. Sutherland DE, Goetz FC, et al. Living-related donor segmental pancreatectomy for transplantation. Transplant Proc. 1980;12(4 Suppl 2):19–25.PubMedGoogle Scholar
  248. Sutherland DE, Gruessner RW, et al. Lessons learned from more than 1,000 pancreas transplants at a single institution. Ann Surg. 2001;233(4):463–501.PubMedPubMedCentralCrossRefGoogle Scholar
  249. Tan J, Yang S, et al. Simultaneous islet and kidney transplantation in seven patients with type 1 diabetes and end-stage renal disease using a glucocorticoid-free immunosuppressive regimen with alemtuzumab induction. Diabetes. 2008;57(10):2666–71.PubMedPubMedCentralCrossRefGoogle Scholar
  250. Tangri N, Grams ME, et al. Multinational assessment of accuracy of equations for predicting risk of kidney failure: a meta-analysis. JAMA. 2016;315(2):164–74.PubMedPubMedCentralCrossRefGoogle Scholar
  251. Tattersall RB. Brittle diabetes revisited: the third Arnold Bloom memorial lecture. Diabet Med. 1997;14(2):99–110.PubMedCrossRefGoogle Scholar
  252. Tattersall R, Gregory R, et al. Course of brittle diabetes: 12 year follow up. BMJ. 1991;302(6787):1240–3.PubMedPubMedCentralCrossRefGoogle Scholar
  253. Tharavanij T, Betancourt A, et al. Improved long-term health-related quality of life after islet transplantation. Transplantation. 2008;86(9):1161–7.PubMedPubMedCentralCrossRefGoogle Scholar
  254. Thompson DM, Meloche M, et al. Reduced progression of diabetic microvascular complications with islet cell transplantation compared with intensive medical therapy. Transplantation. 2011;91(3):373–8.PubMedCrossRefGoogle Scholar
  255. Toso C, Baertschiger R, et al. Sequential kidney/islet transplantation: efficacy and safety assessment of a steroid-free immunosuppression protocol. Am J Transplant. 2006;6(5 Pt 1):1049–58.PubMedCrossRefGoogle Scholar
  256. Toso C, Shapiro AM, et al. Quality of life after islet transplant: impact of the number of islet infusions and metabolic outcome. Transplantation. 2007;84(5):664–6.PubMedCrossRefGoogle Scholar
  257. Turgeon NA, Avila JG, et al. Experience with a novel efalizumab-based immunosuppressive regimen to facilitate single donor islet cell transplantation. Am J Transplant. 2010;10(9):2082–91.PubMedPubMedCentralCrossRefGoogle Scholar
  258. Tyden G, Bolinder J, et al. Improved survival in patients with insulin-dependent diabetes mellitus and end-stage diabetic nephropathy 10 years after combined pancreas and kidney transplantation. Transplantation. 1999;67(5):645–8.PubMedCrossRefGoogle Scholar
  259. Tzakis AG, Ricordi C, et al. Pancreatic islet transplantation after upper abdominal exenteration and liver replacement. Lancet. 1990;336(8712):402–5.PubMedPubMedCentralCrossRefGoogle Scholar
  260. UK Hypoglycaemia Study Group. Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia. 2007;50(6):1140–7.CrossRefGoogle Scholar
  261. van Dellen D, Worthington J, et al. Mortality in diabetes: pancreas transplantation is associated with significant survival benefit. Nephrol Dial Transplant. 2013;28(5):1315–22.PubMedCrossRefGoogle Scholar
  262. Vantyghem MC, Press M. Management strategies for brittle diabetes. Ann Endocrinol (Paris). 2006;67(4):287–96.CrossRefGoogle Scholar
  263. Vantyghem MC, Kerr-Conte J, et al. Primary graft function, metabolic control, and graft survival after islet transplantation. Diabetes Care. 2009;32(8):1473–8.PubMedPubMedCentralCrossRefGoogle Scholar
  264. Vantyghem MC, Defrance F, et al. Treating diabetes with islet transplantation: lessons from the past decade in Lille. Diabetes Metab. 2014a;40(2):108–19.PubMedCrossRefGoogle Scholar
  265. Vantyghem MC, Quintin D, et al. Improvement of electrophysiological neuropathy after islet transplantation for type 1 diabetes: a 5-year prospective study. Diabetes Care. 2014b;37(6):e141–2.PubMedCrossRefGoogle Scholar
  266. Venstrom JM, McBride MA, et al. Survival after pancreas transplantation in patients with diabetes and preserved kidney function. JAMA. 2003;290(21):2817–23.PubMedCrossRefGoogle Scholar
  267. Venturini M, Fiorina P, et al. Early increase of retinal arterial and venous blood flow velocities at color Doppler imaging in brittle type 1 diabetes after islet transplant alone. Transplantation. 2006;81(9):1274–7.PubMedCrossRefGoogle Scholar
  268. Vigersky RA. The benefits, limitations, and cost-effectiveness of advanced technologies in the management of patients with diabetes mellitus. J Diabetes Sci Technol. 2015;9(2):320–30.PubMedPubMedCentralCrossRefGoogle Scholar
  269. Villiger P, Ryan EA, et al. Prevention of bleeding after islet transplantation: lessons learned from a multivariate analysis of 132 cases at a single institution. Am J Transplant. 2005;5(12):2992–8.PubMedCrossRefGoogle Scholar
  270. Vizzardelli C, Potter ED, et al. Automated method for isolation of adrenal medullary chromaffin cells from neonatal porcine glands. Cell Transplant. 2001;10(8):689–96.PubMedCrossRefGoogle Scholar
  271. Voulgari C, Tentolouris N. Brittle diabetes: a contemporary review of the myth and its realization. In: Rigobelo EC, editor. Diabetes – damages and treatments. In: Everlon Cid Rigobelo. Tech; 2011, Janeza Trdine 9, 51000 Rijeka, Croatia. Chapters.Google Scholar
  272. Voulgari C, Pagoni S, et al. ‘Brittleness’ in diabetes: easier spoken than broken. Diabetes Technol Ther. 2012;14(9):835–48.PubMedCrossRefGoogle Scholar
  273. Warnock GL, Kneteman NM, et al. Normoglycaemia after transplantation of freshly isolated and cryopreserved pancreatic islets in type 1 (insulin-dependent) diabetes mellitus. Diabetologia. 1991;34(1):55–8.PubMedCrossRefGoogle Scholar
  274. Warnock GL, Thompson DM, et al. A multi-year analysis of islet transplantation compared with intensive medical therapy on progression of complications in type 1 diabetes. Transplantation. 2008;86(12):1762–6.PubMedCrossRefGoogle Scholar
  275. Watanabe M, Yamashita K, et al. ASKP1240, a fully human anti-CD40 monoclonal antibody, prolongs pancreatic islet allograft survival in nonhuman primates. Am J Transplant. 2013;13(8):1976–88.PubMedCrossRefGoogle Scholar
  276. Weinstock RS, Xing D, et al. Severe hypoglycemia and diabetic ketoacidosis in adults with type 1 diabetes: results from the T1D Exchange clinic registry. J Clin Endocrinol Metab. 2013;98(8):3411–9.PubMedCrossRefGoogle Scholar
  277. Weiss AS, Smits G, et al. Twelve-month pancreas graft function significantly influences survival following simultaneous pancreas-kidney transplantation. Clin J Am Soc Nephrol. 2009;4(5):988–95.PubMedPubMedCentralCrossRefGoogle Scholar
  278. White SA, Shaw JA, et al. Pancreas transplantation. Lancet. 2009;373(9677):1808–17.PubMedCrossRefGoogle Scholar
  279. Workgroup on Hypoglycemia, American Diabetes Association. Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care. 2005;28(5):1245–9.CrossRefGoogle Scholar
  280. Ziaja J, Bozek-Pajak D, et al. Impact of pancreas transplantation on the quality of life of diabetic renal transplant recipients. Transplant Proc. 2009;41(8):3156–8.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Lorenzo Piemonti
    • 1
    • 2
  • Carlo Socci
    • 3
  • Rita Nano
    • 1
  • Paola Maffi
    • 1
    • 4
  • Antonio Secchi
    • 5
    • 2
  1. 1.Diabetes Research Institute (SR-DRI)IRCCS San Raffaele Scientific InstituteMilanItaly
  2. 2.Internal Medicine and Transplant Unit, Vita-Salute San Raffaele UniversityMilanItaly
  3. 3.Unit of Transplant SurgeryIRCCS San Raffaele Scientific InstituteMilanItaly
  4. 4.Clinical Transplant UnitIRCCS San Raffaele Scientific InstituteMilanItaly
  5. 5.Internal Medicine and Transplant UnitMilanItaly

Personalised recommendations